INDSWFTLTDPharmaceuticals & Biotechnology
Ind Swift — Cash Flow Statement
₹15.76
+0.00%
Ind Swift Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -24.87 Cr | -13.21 Cr | 42.22 Cr | 30.63 Cr | — |
| Capital Expenditure | -40.72 Cr | -28.49 Cr | -30.83 Cr | -19.58 Cr | — |
| End Cash Position | 69.51 Cr | 63.14 Cr | 13.33 Cr | 16.18 Cr | — |
| Beginning Cash Position | 63.14 Cr | 13.33 Cr | 16.18 Cr | 28.99 Cr | — |
| Changes In Cash | 6.37 Cr | 49.81 Cr | -2.85 Cr | -12.81 Cr | — |
| Financing Cash Flow | -12.71 Cr | -42.08 Cr | -46.56 Cr | -44.59 Cr | — |
| Net Other Financing Charges | 0.70 Cr | -0.03 Cr | -0.40 Cr | -0.18 Cr | — |
| Interest Paid Cff | -39.28 Cr | -63.43 Cr | -63.69 Cr | -58.27 Cr | — |
| Net Issuance Payments Of Debt | 25.86 Cr | 21.38 Cr | 17.54 Cr | 13.85 Cr | — |
| Net Short Term Debt Issuance | -1.59 Cr | -585.01 Cr | 173.15 Cr | 37.99 Cr | — |
| Net Long Term Debt Issuance | 27.46 Cr | 606.39 Cr | -155.61 Cr | -24.14 Cr | — |
| Investing Cash Flow | 3.23 Cr | 76.61 Cr | -29.34 Cr | -18.42 Cr | — |
| Net Other Investing Changes | 38.57 Cr | 7.21 Cr | 0.71 Cr | 0.10 Cr | — |
| Interest Received Cfi | 5.37 Cr | 1.94 Cr | 0.77 Cr | 1.06 Cr | — |
| Net Investment Purchase And Sale | 0.00 | 95.95 Cr | 0.00 | 0.00 | — |
| Sale Of Investment | 0.00 | 95.95 Cr | 0.00 | 0.00 | — |
| Net PPE Purchase And Sale | -40.72 Cr | -28.49 Cr | -30.83 Cr | -19.58 Cr | — |
| Purchase Of PPE | -40.72 Cr | -28.49 Cr | -30.83 Cr | -19.58 Cr | — |
| Operating Cash Flow | 15.86 Cr | 15.28 Cr | 73.05 Cr | 50.20 Cr | — |
| Change In Working Capital | -24.10 Cr | -47.10 Cr | 22.36 Cr | -6.98 Cr | — |
| Change In Other Current Liabilities | 37.37 Cr | -29.62 Cr | 51.36 Cr | -14.93 Cr | — |
| Change In Other Current Assets | -10.10 Cr | 1.25 Cr | 4.49 Cr | -2.10 Cr | — |
| Change In Inventory | -43.16 Cr | 25.26 Cr | -19.77 Cr | -6.74 Cr | — |
| Change In Receivables | -8.21 Cr | -43.98 Cr | -13.72 Cr | 16.79 Cr | — |
| Other Non Cash Items | 33.77 Cr | 60.81 Cr | 56.31 Cr | 44.93 Cr | — |
| Provisionand Write Offof Assets | 1.67 Cr | 0.00 | 0.11 Cr | 1.56 Cr | — |
| Depreciation And Amortization | 23.50 Cr | 27.11 Cr | 28.67 Cr | 32.07 Cr | — |
| Depreciation | 23.50 Cr | 27.11 Cr | 28.67 Cr | 32.07 Cr | — |
| Pension And Employee Benefit Expense | 1.80 Cr | 0.80 Cr | 0.37 Cr | -0.61 Cr | — |
| Gain Loss On Investment Securities | -28.73 Cr | -38.39 Cr | -0.24 Cr | -0.03 Cr | — |
| Net Income From Continuing Operations | 7.94 Cr | 12.06 Cr | -34.54 Cr | -20.34 Cr | — |
| Repayment Of Debt | — | — | -207.89 Cr | -74.19 Cr | -0.05 Cr |
| Issuance Of Debt | — | — | 52.29 Cr | 50.06 Cr | — |
| Long Term Debt Payments | — | — | -207.89 Cr | -74.19 Cr | -0.05 Cr |
| Long Term Debt Issuance | — | — | 52.29 Cr | 50.06 Cr | — |
| Taxes Refund Paid | — | — | 0.00 | -0.42 Cr | -0.32 Cr |
| Net Foreign Currency Exchange Gain Loss | — | — | — | — | -5.95 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Ind Swift
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.